$59.8MSeries B, 20 January 2026
Funds a Phase 2 trial of Deraphan for Alzheimer's agitation in Europe, the US and Canada.
- Amount
- $59.8M
- Stage
- Series B
- Announced
- 20 January 2026
- Lead
- Gimv
- Other investors
- EQT Life Sciences, Fountain Healthcare Partners, LifeArc Ventures, Carma Fund, Modi Ventures, Andera Partners, LBBW
- Use of funds
- Funds a Phase 2 trial of Deraphan for Alzheimer's agitation in Europe, the US and Canada.
- Checked
- Announced by the company
- Sources
- Heidelberg biotech Exciva raises EUR 51M Series B for Alzheimer drugs inderes.fi
Heidelberg biotech Exciva raises EUR 51M Series B for Alzheimer drugs trendingtopics.eu